Hologic, Inc. (NASDAQ:HOLX) Holdings Raised by Denali Advisors LLC

Denali Advisors LLC boosted its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,000 shares of the medical equipment provider’s stock after acquiring an additional 300 shares during the quarter. Denali Advisors LLC’s holdings in Hologic were worth $371,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. Principal Securities Inc. bought a new position in shares of Hologic in the fourth quarter valued at approximately $115,000. Jump Financial LLC acquired a new position in shares of Hologic during the 4th quarter valued at $419,000. Independent Advisor Alliance increased its position in shares of Hologic by 28.6% during the 4th quarter. Independent Advisor Alliance now owns 4,828 shares of the medical equipment provider’s stock valued at $345,000 after purchasing an additional 1,073 shares during the period. Brown Advisory Inc. raised its stake in shares of Hologic by 0.3% in the 4th quarter. Brown Advisory Inc. now owns 74,438 shares of the medical equipment provider’s stock worth $5,319,000 after buying an additional 192 shares in the last quarter. Finally, Norges Bank bought a new position in Hologic during the fourth quarter valued at about $217,529,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several research reports. Evercore ISI boosted their price target on shares of Hologic from $76.00 to $78.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 30th. JPMorgan Chase & Co. increased their target price on shares of Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. StockNews.com lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Wednesday. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Trading Down 0.8 %

NASDAQ:HOLX opened at $82.00 on Wednesday. The company has a market capitalization of $19.14 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.53 and a beta of 0.98. The stock’s 50 day moving average price is $80.36 and its 200 day moving average price is $76.92. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.32 and a current ratio of 3.99. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 17.59% and a return on equity of 19.53%. Hologic’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.93 EPS. On average, research analysts forecast that Hologic, Inc. will post 4.09 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the transaction, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares of the company’s stock, valued at approximately $858,927.24. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Christiana Stamoulis sold 9,039 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $79.50, for a total value of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares in the company, valued at approximately $3,615,024. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock valued at $1,469,973 over the last quarter. Insiders own 1.75% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.